 Repare Therapeutics Inc NASDAQ: RPTX announced the presentation of preliminary Phase 1 monotherapy data from its Phase 12 TRESR trial of RP-3500 for solid tumors with specific synthetic-lethal genomic alterations. Data were presented at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. 